American Capital Advisory’s AbbVie ABBV Stock Holding History

American Capital Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$777K	Buy	3,087 +221	+8%	+$47.5K	0.28%	59
2026 Q1	$623K	Buy	2,866 +19	+0.7%	+$4.21K	0.25%	66
2025 Q4	$651K	Buy	2,847 +12	+0.4%	+$2.73K	0.28%	61
2025 Q3	$656K	Hold	2,835	–	–	0.3%	59
2025 Q2	$526K	Buy	2,835 +19	+0.7%	+$3.53K	0.26%	64
2025 Q1	$590K	Buy	2,816 +81	+3%	+$15.7K	0.32%	57
2024 Q4	$486K	Hold	2,735	–	–	0.27%	68
2024 Q3	$540K	Hold	2,735	–	–	0.31%	60
2024 Q2	$424K	Hold	2,735	–	–	0.3%	61
2024 Q1	$436K	Hold	2,735	–	–	0.38%	61
2023 Q4	$424K	Buy	+2,735	New	+$399K	0.3%	61

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

American Capital Advisory's ABBV Position: Q2 2026 in Review

American Capital Advisory increased its AbbVie (ABBV) stake by 7.7% in Q2 2026, buying an estimated $47.5K and bringing the position to 3,087 shares worth $777K. The position accounts for 0.28% of the portfolio, ranked #59.

American Capital Advisory first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

American Capital Advisory held 3,087 shares of AbbVie worth $777K as of Q2 2026.
American Capital Advisory bought 221 AbbVie shares in Q2 2026, an estimated $47.5K.
AbbVie made up 0.28% of American Capital Advisory's portfolio in Q2 2026, its #59 holding.
American Capital Advisory first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.